CN115175932B - 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 - Google Patents

用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Info

Publication number
CN115175932B
CN115175932B CN202080063538.0A CN202080063538A CN115175932B CN 115175932 B CN115175932 B CN 115175932B CN 202080063538 A CN202080063538 A CN 202080063538A CN 115175932 B CN115175932 B CN 115175932B
Authority
CN
China
Prior art keywords
binding polypeptide
binding
soluble
brain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080063538.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115175932A (zh
Inventor
金明
L·普拉蒂尔
D·雷泽克
D·塞尔科
T·特拉瓦林
D·沃尔什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Brigham and Womens Hospital Inc
Original Assignee
Sanofi Aventis France
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France, Brigham and Womens Hospital Inc filed Critical Sanofi Aventis France
Priority to CN202511495659.3A priority Critical patent/CN121949538A/zh
Priority to CN202511495657.4A priority patent/CN121800915A/zh
Publication of CN115175932A publication Critical patent/CN115175932A/zh
Application granted granted Critical
Publication of CN115175932B publication Critical patent/CN115175932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080063538.0A 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 Active CN115175932B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202511495659.3A CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495657.4A CN121800915A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874724P 2019-07-16 2019-07-16
US62/874,724 2019-07-16
PCT/US2020/042161 WO2021011673A2 (en) 2019-07-16 2020-07-15 Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202511495657.4A Division CN121800915A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495659.3A Division CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Publications (2)

Publication Number Publication Date
CN115175932A CN115175932A (zh) 2022-10-11
CN115175932B true CN115175932B (zh) 2025-10-31

Family

ID=71895293

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080063538.0A Active CN115175932B (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495659.3A Pending CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495657.4A Pending CN121800915A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202511495659.3A Pending CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495657.4A Pending CN121800915A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Country Status (7)

Country Link
US (1) US20230107034A1 (https=)
EP (1) EP3999532A2 (https=)
JP (1) JP7685985B2 (https=)
KR (1) KR20220034857A (https=)
CN (3) CN115175932B (https=)
CA (1) CA3147239A1 (https=)
WO (1) WO2021011673A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2026082154A1 (en) * 2024-10-18 2026-04-23 Lepu Biopharma Co., Ltd. Anti-beta amyloid antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101820911A (zh) * 2007-06-12 2010-09-01 Ac免疫有限公司 β淀粉样蛋白的人源化抗体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
EP1545582A4 (en) 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
US20160213794A1 (en) * 2002-10-01 2016-07-28 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2560681A4 (en) * 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
SMT202000340T1 (it) * 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101820911A (zh) * 2007-06-12 2010-09-01 Ac免疫有限公司 β淀粉样蛋白的人源化抗体

Also Published As

Publication number Publication date
WO2021011673A2 (en) 2021-01-21
JP7685985B2 (ja) 2025-05-30
CN121949538A (zh) 2026-05-01
WO2021011673A3 (en) 2021-07-01
CN115175932A (zh) 2022-10-11
JP2022541459A (ja) 2022-09-26
KR20220034857A (ko) 2022-03-18
CN121800915A (zh) 2026-04-07
CA3147239A1 (en) 2021-01-21
US20230107034A1 (en) 2023-04-06
EP3999532A2 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
JP7608404B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
EP3160999B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
TWI741987B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
AU2008334637B2 (en) Antigen binding proteins
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
CN104428315B (zh) 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
JP7352973B2 (ja) 二重特異性抗体及びその使用
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
KR20160037173A (ko) 치료학적 융합 단백질
CN115697393A (zh) 抗PHF-tau抗体及其用途
WO2019001559A1 (zh) 抗gitr抗体、其抗原结合片段及其医药用途
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
CA2990555C (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
HK40115197A (zh) 抗序列相似家族19成员a5抗体用於治疗和诊断情绪障碍的用途
KR20260053095A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
HK1206365B (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant